TG Therapeutics | TGTX - Current Liabilities


TG Therapeutics reported $268.49M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Alaunos Therapeutics USD 595K 218K Mar/2026
Amgen USD 25.5B 547M Jun/2026
Ardelyx USD 109.57M 20.96M Mar/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Bayer EUR 32.27B 1.19B Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
Corcept Therapeutics USD 153.8M 4.62M Jun/2026
Curis USD 14.97M 898K Mar/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novavax USD 330.57M 11.89M Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
TG Therapeutics USD 268.49M 81.38M Jun/2026
Verastem USD 66.84M 5.42M Mar/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026